Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
December 30 2022 - 8:10AM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental
stage biopharmaceutical company focused on merging traditional
therapeutics with psychedelic research, today announced positive
interim data from its dose optimization study of SPU-21 joint
homing peptides for subcutaneous administration of anti-arthritic
agents. Silo Pharma is pursuing a development plan utilizing its
liposomal joint homing peptides as a potential therapy for
rheumatoid arthritis (RA).
In the most recent phase of this ongoing animal study, tests
were conducted to evaluate the disease-suppressive effects of an
SPU-21 peptide-guided anti-arthritis drug versus the drug alone.
The drug used in the study was dexamethasone (DEX), a
corticosteroid used for its anti-inflammatory and immunosuppressant
effects. Earlier results of the same study successfully
demonstrated that the subcutaneous (SC) route of liposomal
administration (small needle injection into shallow soft tissue
just under the layer of skin) is well-suited for use in targeted
drug delivery of anti-arthritic agents.
“We believe that the positive results of these latest tests show
that our peptide with DEX given subcutaneously was effective in
controlling arthritis progression. The effect of lipo-DEX was
superior to that of DEX alone when both were administered via the
SC route,” said Eric Weisblum, Chief Executive Officer of Silo
Pharma. “Since patients widely prefer SC administration over
intravenous (IV) infusion for multiple reasons, we believe the
superiority and practicality of our liposomal joint homing peptide
bode well for broad market potential. Meanwhile, we continue to
explore other novel therapeutics for optimal pairing with SPU-21,
targeting rheumatoid arthritis as our initial indication.”
Silo Pharma is advancing the development of SPU-21 liposomal
joint homing peptides in collaboration with the University of
Maryland, Baltimore (UMB).
About Silo PharmaSilo Pharma. Inc. is a development-stage
biopharmaceutical company focused on merging traditional
therapeutics with psychedelic research for people suffering from
indications such as PTSD, Alzheimer’s disease, and other rare
neurological disorders. Silo’s mission is to identify assets to
license and fund the research which we believe will be
transformative to the well-being of patients and the healthcare
industry. For more information, visit www.silopharma.com.
Forward-Looking StatementsAll statements other than statements
of historical fact in this announcement are forward-looking
statements that involve known and unknown risks and uncertainties
and are based on current expectations and projections about future
events and financial trends that the Company believes may affect
its financial condition, results of operations, business strategy,
and financial needs. Investors can identify these forward-looking
statements by words or phrases such as "may," "will," "expect,"
"anticipate," "aim," "estimate," "intend," "plan," "believe,"
"potential," "continue," "is/are likely to" or other similar
expressions. The Company undertakes no obligation to update
forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's filings with the SEC.
Contact 800-705-0120investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Apr 2023 to Apr 2024